Clinical Trials Logo
NCT number NCT03463057
Study type Interventional
Source Stichting Hemato-Oncologie voor Volwassenen Nederland
Contact M. Nijland, MD
Phone +31 50 3611761
Email m.nijland@umcg.nl
Status Not yet recruiting
Phase Phase 2
Start date April 2018
Completion date April 2025

Clinical Trial Summary

The prognosis of Diffuse Large B cell Lymphoma (DLBCL) patients with an early relapse is dismal. Atezolizumab has shown promising activity in relapsed DLBCL patients. Toxicity data on atezolizumab are available for > 6000 patients and is manageable. The assumption of this study is that atezolizumab consolidation will result in higher disease free survival by eradicating minimal residual disease In melanoma and lung cancer consolidation immunotherapy after chemoradiotherapy has shown an increase in survival.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Completed NCT00513175 - Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia N/A
Completed NCT00342121 - Influence of Corn Farming on the Immune System
Active, not recruiting NCT01101581 - Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL Phase 1/Phase 2
Recruiting NCT02702492 - PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) Phase 1
Terminated NCT00814983 - Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft Phase 1/Phase 2
Completed NCT00891592 - Umbilical Cord Blood Transplant for Hematological Malignancies Phase 1
Completed NCT00546793 - Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL Phase 1/Phase 2
Not yet recruiting NCT02847949 - A Study of IGN002 for Refractory NHL Phase 2
Recruiting NCT02315612 - Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies Phase 1
Recruiting NCT00515892 - Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease Phase 1
Completed NCT00421395 - Safety Study of NHL With 90Y-hLL2 IgG Phase 1/Phase 2
Terminated NCT02110563 - Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma Phase 1
Terminated NCT00471367 - Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877 Phase 1